Loading
Life sciences · Journal article
PLOS One · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Acquired resistance to epidermal growth factor receptor (EGFR)-targeted therapy remains a major obstacle in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). This study investigated whether repurposing mebendazole (MBZ), a microtubule-disrupting agent, could restore sensitivity to gefitinib in gefitinib-resistant HCC827 GR5 cells. Gefitinib monotherapy showed minimal cytotoxicity, reducing cell viability only marginally (92.7 ± 1.5%), whereas MBZ significantly decreased viability to 79.7 ± 0.6% at 0.1 µM and 29.7 ± 0.6% at 0.5 µM (p < 0.001). Combination treatment (gefitinib 1 µM + MBZ 0.1 µM) further reduced viability to 37.7 ± 0.6% (p < 0.001). Mechanistically, alkaline comet assay revealed significantly increased single-strand DNA damage in the combination group (tail intensity 22.33 ± 0.56%, p < 0.001), while neutral comet assay confirmed elevated double-strand DNA breaks. MBZ also induced dose-dependent γ-H2AX activation (p < 0.001), supporting replication stress-associated DNA damage signaling. In vivo, combination therapy significantly suppressed tumor growth, prolonging tumor doubling time from 6.2 days in controls to 25 days and increasing growth delay to 18.8 days (p < 0.01), without substantial systemic toxicity. Collectively, these findings identify replication stress vulnerability as a therapeutically exploitable axis and support MBZ repurposing as an adjuvant strategy to overcome gefitinib resistance.